𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Epidermal growth factor inhibits the growth of TE8 esophageal cancer cells through the activation of STAT1

✍ Scribed by Makoto Ichiba; Yoshiji Miyazaki; Shinji Kitamura; Tatsuya Kiyohara; Yasuhisa Shinomura; Yuji Matsuzawa

Publisher
Springer Japan
Year
2002
Tongue
English
Weight
127 KB
Volume
37
Category
Article
ISSN
0944-1174

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Targeting the epidermal growth factor re
Targeting the epidermal growth factor receptor by erlotinib (Tarceva™) for the treatment of esophageal cancer
✍ Andreas P. Sutter; Michael Höpfner; Alexander Huether; Kerstin Maaser; Hans Sche 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 French ⚖ 370 KB 👁 1 views

## Abstract Esophageal cancer is the sixth most common cause of cancer‐related death worldwide. Because of very poor 5‐year survival new therapeutic approaches are mandatory. Erlotinib (Tarceva™), an inhibitor of epidermal growth factor receptor tyrosine kinase (EGFR‐TK), potently suppresses the gr

5′-Nitro-indirubinoxime inhibits epiderm
5′-Nitro-indirubinoxime inhibits epidermal growth factor- and phorbol ester-induced AP-1 activity and cell transformation through inhibition of phosphorylation of Pin1
✍ Prem Khanal; Hoo-Kyun Choi; Gwang Mo Namgoong; Sang-Gun Ahn; Jung-Hoon Yoon; Hon 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 443 KB

## Abstract 5′‐Nitro‐indirubinoxime (5′‐NIO), a derivative of indirubin, exhibits anti‐cancer activity in a variety of human cancer cells. However, the underlying molecular mechanisms and molecular target(s) of the chemopreventive activities of 5′‐NIO remain unknown. Here, we report that 5′‐NIO inh